Literature DB >> 22576425

Differentiating between tuberculosis-related and lymphoma-related lymphocytic pleural effusions by measuring clinical and laboratory variables: is it possible?

Leila Antonangelo1, Francisco Suso Vargas, Eduardo Henrique Genofre, Caroline Maris Neves de Oliveira, Lisete Ribeiro Teixeira, Roberta Karla Barbosa de Sales.   

Abstract

OBJECTIVE: To describe clinical and laboratory characteristics in patients with tuberculosis-related or lymphoma-related lymphocytic pleural effusions, in order to identify the variables that might contribute to differentiating between these diseases.
METHODS: This was a retrospective study involving 159 adult HIV-negative patients with tuberculosis-related or lymphoma-related lymphocytic effusions (130 and 29 patients, respectively), treated between October of 2008 and March of 2010 at the Pleural Diseases Outpatient Clinic of the University of São Paulo School of Medicine Hospital das Clínicas Heart Institute, in the city of São Paulo, Brazil.
RESULTS: Mean age and the mean duration of symptoms were lower in the tuberculosis group than in the lymphoma group. The levels of proteins, albumin, cholesterol, amylase, and adenosine deaminase (ADA) in pleural fluid, as well as the serum levels of proteins, albumin, and amylase, were higher in the tuberculosis group, whereas serum cholesterol and triglycerides were higher in the lymphoma group. Pleural fluid leukocyte and lymphocyte counts were higher in the tuberculosis group. Of the tuberculosis group patients, none showed malignant cells; however, 4 showed atypical lymphocytes. Among the lymphoma group patients, cytology for neoplastic cells was positive, suspicious, and negative in 51.8%, 24.1%, and 24.1%, respectively. Immunophenotyping of pleural fluid was conclusive in most of the lymphoma patients.
CONCLUSIONS: Our results demonstrate clinical and laboratory similarities among the patients with tuberculosis or lymphoma. Although protein and ADA levels in pleural fluid tended to be higher in the tuberculosis group than in the lymphoma group, even these variables showed an overlap. However, none of the tuberculosis group patients had pleural fluid ADA levels below the 40-U/L cut-off point.

Entities:  

Mesh:

Year:  2012        PMID: 22576425     DOI: 10.1590/s1806-37132012000200006

Source DB:  PubMed          Journal:  J Bras Pneumol        ISSN: 1806-3713            Impact factor:   2.624


  5 in total

1.  Preliminary Cytomorphologic Diagnosis of Hematolymphoid Malignancies in Effusions: A Cyto-histo Correlation with Lessons on Restraint.

Authors:  Bidish K Patel; Debasis Gochhait; Sreerekha Jinkala; Vidhyalakshmi Rangarajan; Narasimhapriyan Kannan; S Durgadevi; Neelaiah Siddaraju
Journal:  J Cytol       Date:  2022-05-30       Impact factor: 1.577

2.  Elevated Adenosine Deaminase in Pleural Effusion A Case of Non-Hodgkin Lymphoma Misdiagnosis.

Authors:  Tiago Seco; Ana Margarida Cerqueira; Ana Luís Ferreira; Ana Costa; Carlos Fernandes; Jorge Cotter
Journal:  Eur J Case Rep Intern Med       Date:  2020-05-06

3.  Differential diagnosis between lymphoma-associated malignant pleural effusion and tuberculous pleural effusion.

Authors:  Chang Ho Kim; Hong Geun Oh; Sang Yub Lee; Jae Kwang Lim; Yong Hoon Lee; Hyewon Seo; Seung Soo Yoo; Shin Yup Lee; Seung Ick Cha; Jae Yong Park; Jaehee Lee
Journal:  Ann Transl Med       Date:  2019-08

4.  Diagnostic accuracy of adenosine deaminase for pleural tuberculosis in a low prevalence setting: A machine learning approach within a 7-year prospective multi-center study.

Authors:  Alberto Garcia-Zamalloa; Diego Vicente; Rafael Arnay; Arantzazu Arrospide; Jorge Taboada; Iván Castilla-Rodríguez; Urko Aguirre; Nekane Múgica; Ladislao Aldama; Borja Aguinagalde; Montserrat Jimenez; Edurne Bikuña; Miren Begoña Basauri; Marta Alonso; Emilio Perez-Trallero
Journal:  PLoS One       Date:  2021-11-04       Impact factor: 3.240

5.  Pleural fluid adenosine deaminase (pfADA) in the diagnosis of tuberculous effusions in a low incidence population.

Authors:  David T Arnold; Rahul Bhatnagar; Lynette D Fairbanks; Natalie Zahan-Evans; Amelia O Clive; Anna J Morley; Andrew R L Medford; Nicholas A Maskell
Journal:  PLoS One       Date:  2015-02-03       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.